vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Core Viewpoint - vTv Therapeutics Inc. is making significant progress in the development of cadisegliatin, a potential first-in-class oral adjunctive therapy for type 1 diabetes, with expectations to complete patient enrollment in the CATT1 Phase 3 trial by the third quarter of 2026 [2][5]. Financial Highlights - The company reported a cash position of $88.9 million as of December 31, 2025, a substantial increase from $36.7 million in the previous year, primarily due to an $80 million financing round [4][8]. - Research and Development (R&D) expenses for the fourth quarter of 2025 were $3.9 million, up from $2.2 million in the same period of 2024, driven by increased spending on cadisegliatin [6][9]. - General and Administrative (G&A) expenses for the fourth quarter of 2025 were $4.0 million, compared to $2.7 million in the fourth quarter of 2024, reflecting higher payroll and legal expenses [9][11]. - The net loss attributable to vTv shareholders for the year ended December 31, 2025, was $27.0 million, or $3.20 per basic share, compared to a net loss of $18.5 million, or $3.20 per basic share, in 2024 [11]. Corporate Developments - In February 2026, vTv received a $20 million upfront payment from Newsoara Biopharma Inc. as part of an amended licensing agreement, which also includes potential future milestone payments totaling up to approximately $115 million [5][12]. - The company has expanded its intellectual property estate supporting cadisegliatin and initiated patient dosing in the Phase 3 CATT1 trial during 2025 [2][5]. - vTv submitted a Phase 2 clinical study protocol for cadisegliatin in type 2 diabetes to the United Arab Emirates Department of Health in December 2025 [5]. Clinical Progress - The CATT1 Phase 3 trial for cadisegliatin has seen slower-than-expected patient enrollment; however, the company has increased the number of participating sites and enhanced engagement efforts, leading to improved enrollment momentum [2][5]. - Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA), indicating its potential as a significant treatment option for type 1 diabetes [12][14].